БОЛЕЗНЬ ПАРКИНСОНА И ЕГО ЛЕЧЕНИЕ ПРЕПАРАТАМИ ЛЕВОДОПЫ
Keywords:
Keywords: Parkinson's disease, dopamine, glutamate, Levodopa, fluctuation, dyskinesia, benserazide, black substance, COMT inhibitorAbstract
Abstract: This article examines the effect of levodopa drugs in the treatment of Parkinson's disease. It also provides an overview of scientific research conducted in this area and analyzes the results obtained, which demonstrate how levodopa drugs can positively or negatively affect the body during treatment. In conclusion, the article highlights the importance of using levodopa drugs in Parkinson's disease
References
Hurwitz B. (2014). Urban observation and sentiment in James Parkinson’s Essay on the Shaking Palsy (1817). Lit Med. Spring, 74–104;
Аляутдин Р.Н. Фармакология: Учебник. – 2-е изд., испр. – М: ГЭОТАР – МЕД, 2004. – 592с.: ил.
Голубев В.Л. Лечение болезни Паркинсона: решенные и нерешенные вопросы. В кн.: Избранные лекции по неврологии. Под ред. В.Л. Голубева. M., Эйдос Медиа; 2006. с. 395—421.
Fahn S. Parkinsonism. Complications of long-term levodopa therapy. In: L.P. Ronald, editor. Merritt's Textbook of Neurology. 9-th ed. New York, Williams&Wilkins; 1995. p. 726.
Rajput A.H., Fenton M.E., Biridi S.et al. Clinical-pathological studyof levodopa complications. Mov Disord 2002;17(2):289—96.
Stacy M., Bowron A., Guttman M. et al. Indentification of motor and nonmo tor wearing-off in Parkinson's disease:comparison of a patient questionnaire ver sus a clinical assessment. Mov Disord 2005;20(6):726—33
Eichhorn T.E., Schrag A., Trenkwalder C. et al. Effectiveness of slow release L-DOPA-benserazide in treatment of end-of-dose akinesia in Parkinson disease [in German]. Nervenarzt 1995;66:933—41.
Нодель М.Р., Яхно Н.Н., Артемьев Д.В. Применение Мадопара ГСС и Мадопара Диспергируемого при болезни Паркинсона. Невролжурн 2000;(2):42—6.
Entacapone improves motor fluctuations in levodopa-treated
Parkinson's disease patients. Parkinson Study Group. Ann Neurol 1997;42: 747—55.
